Ventricular assist devices (VADs) became in recent years the standard of care therapy for advanced heart failure with hemodynamic compromise. With the steadily growing population of device recipients, various postimplant complications have been reported, mostly associated with the hypershear generated by VADs that enhance their thrombogenicity by activating platelets. Although VAD design optimization can significantly improve its thromboresistance, the implanted VAD need to be evaluated as part of a system. Several clinical studies indicated that variability in implantation configurations may contribute to the overall system thrombogenicity. Numerical simulations were conducted in the HeartAssist 5 (HA5) and HeartMate II (HMII) VADs in the following implantation configurations: 1) inflow cannula angles: 115° and 140° (HA5); 2) three VAD circumferential orientations: 0°, 30°, and 60° (HA5 and HMII); and 3) 60° and 90° outflow graft anastomotic angles with respect to the ascending aorta (HA5). The stress accumulation of the platelets was calculated along flow trajectories and collapsed into a probability density function, representing the "thrombogenic footprint" of each configuration-a proxy to its thrombogenic potential (TP). The 140° HA5 cannula generated lower TP independent of the circumferential orientation of the VAD. Sixty-degree orientation generated the lowest TP for the HA5 versus 0° for the HMII. An anastomotic angle of 60° resulted in lower TP for HA5. These results demonstrate that optimizing the implantation configuration reduces the overall system TP. Thromboresistance can be enhanced by combining VAD design optimization with the surgical implantation configurations for achieving better clinical outcomes of implanted VADs. ASAIO Journal 2017; 63:285-292.
Mechanical circulatory support (MCS) has emerged as a mainstay of therapy for failing patients with advanced New York Heart Association (NYHA) class III and IV (American Heart Association stage C and D) heart failure.
1,2 Specifically, ventricular assist devices (VADs) have emerged as the dominant MCS device implanted, either in a single or dual ventricular configurations, that is, left ventricular assist device or biventricular assist device, respectively. [3] [4] [5] [6] [7] Several VADs are currently approved by the Food and Drug Administration for bridge-to-transplant and as destination therapy. Despite the hemodynamic efficacy of VADs for restoring failing circulation, they remain plagued by a significant rate of adverse events. [8] [9] [10] [11] For instance, thrombosis, 12 which may lead to a range of complications including thromboembolic events with frank stroke and other central nervous system and peripheral sequelae, intradevice thrombus accumulation, reduced pump output with potential complete pump stop. [13] [14] [15] [16] [17] [18] [19] To prevent VAD-related thrombosis, antithrombotic agents-antiplatelet and anticoagulant medications, which to date have had only partial efficacy in limited thrombosis-are mandated to MCS patients. 20, 21 In fact, recent work has demonstrated mechanistic limitations of agents such as aspirin in limited VAD-related thrombosis. 22, 23 A dominant contributing mechanism driving thrombosis in MCS systems is the supraphysiologic hypershear environment, that is, highly dynamic elevated shear stress, imparted to blood by virtue of the propulsion means and geometries of current VAD systems. 24, 25 Specifically, present systems, being predominantly of continuous flow design, rotate at high speeds, with extremely narrow gap clearances between the impeller and the pump housing, inducing elevated shear stresses on platelets and red blood cells as they traverse the VAD, resulting in cumulative platelet damage with resultant platelet activation, hemolysis, and initiation and propagation of thrombus formation. [24] [25] [26] [27] In an attempt to reduce shear-mediated platelet activation, device design optimization processes, for example, Device Thrombogenicity Emulation methodology, 25, 28 have successfully demonstrated their efficacy for enhancing the device thromboresistance. 24, 25, 29 In addition, the efficacy of such methodology for reducing VAD thrombogenicity has been demonstrated overweighing typical pharmacologic management in which current clinical agents in use. 22, 23 In considering an implanted VAD, the pump must be regarded as an element of a larger MCS system. Within the system, blood flow patterns may be significantly affected by specific implantation configuration geometries and orientations that may contribute to unwanted nonphysiologic flow, turbulence, and elevated dynamic shear stresses. The final MCS system configuration in a given patient depends on variables ranging
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Thrombogenic Potential WEI-CHE CHIu,* YArED AlEMu,* AllISoN J. MClArTY, † SHMuEl EINAV,* MArVIN J. SlEpIAN,* ‡ AND DANNY BluESTEIN* from the individual surgical technique to the patient-specific anatomy, for instance, the interface between the VAD and the heart that establishes the pump inflow conditions, the nature of the inflow cannula with its specific geometry, and the angulation and radial orientation of the pump with respect to the ventricular apex. 30 Furthermore, additional variables are introduced by the specific angulation of the outflow graft and the anastomotic angle of reconnection to the ascending aorta. The current study hypothesized that these system element variables (e.g., orientation and angulation) may adversely affect the overall thrombogenicity of the implanted MCS system, and such an impact was evaluated by using in silico modeling. Specifically, the following surgical implantation and geometric design variables were studied: 1) inflow cannula elbow angle-115° and 140°-for the HeartAssist 5 VAD (HA5; MicroMed Cardiovascular Inc., Houston, TX); 2) VAD rotational orientation-three circumferential orientations of 0°, 30°, and 60°, with respect to the pump sagittal plane-for both the HA5 and HeartMate II (HMII; Thoratec Corp., pleasanton, CA); and 3) outflow graft orientation-anastomotic angles of 60° and 90° with respect to the ascending aorta.
Materials and Methods

Geometries and Mesh Preparation and Numerical Simulations
Ventricular assist devices and inflow cannulae Two axial cfVADs (continuous flow VADs), HA5, for which device thrombogenicity was optimized in the previous studies, 24, 25 and HMII, were employed in the current study (Figure 1 , exterior). Both HA5 and HMII contain a three-straight-fin inflow stator (Figure 1 , interior-I), followed by the 3-to-6 (i.e., three and six blades corresponding to the first and the second stage of HA5 impeller) and 3 blades impellers for HA5 and HMII (Figure 1 , interior-r), respectively. Besides, these cfVADs' impellers rotate in opposite directions, that is, clockwise and counterclockwise of the flow directions for HA5 and HMII, respectively. Downstream of the impellers are the outflow stators which contain identical numbers of fins as the corresponding impeller blades (Figure 1, interior-o) . Both cfVADs connect to the apex of the left ventricle via their rigid elbow inflow cannulae; between the suturing ring and the elbow, HMII inflow cannula has a flexible section, whereas the HA5 inflow cannula is a rigid unit (Figure 1, assembled) . The impact from such differences has been reported clinically as the flexibility of HMII inflow cannula may lead to postimplant device migration, and alter the implanted device geometry. 30 The HA5 inflow cannula is directly inserted and oriented into the cored ventricular apex, and the affixed suture ring is sewn to an apical fixation ring; in contrast, the HMII inflow cannula is inserted, oriented, and secured to the inflow cuff which is affixed to the cored ventricular apex. Downstream of the outflow stators, the HMII has a rigid elbow outflow cannula which connects to the outflow graft; conversely, the HA5 outflow graft connects directly downstream of its outflow stator (Figure 1, assembled) . These surgical techniques afford the freedom for circumferential orientation for gaining a better individualized anatomical fit and orientation ( Figure 2B) . Two HA5's inflow cannula elbow angles, 115° and 140° ( Figure 2A) , and three inflow cannula circumferential orientations, 0°, 30°, and 60°, for both HA5 and HMII ( Figure 2C ) were studied. The HA5's inflow cannula elbow angles were determined according to the manufacturer's designs for adult and pediatric patients. The three inflow cannula circumferential orientations were determined according to the three-fin inflow stator design (120° radially apart), which generates a 60° of circumferential freedom when connecting the inflow cannula to the VAD because of the alignment of the elbow arm and the inflow stator fin. ANSYS DesignModeler and Meshing (ANSYS Inc., Canonsburg, pA) was used for preparing geometries and the associated volumetric meshes. Mesh independence studies were conducted with various mesh densities (~12, 15, and 21 M and ~13, 25, and 28 M elements for HA5 and HMII, respectively), and were achieved with ~12 and 28 M elements for HA5 and HMII, respectively.
The Fluent CFD solver (ANSYS Inc.) was used for conducting fluid structure interaction (FSI) simulations, as described in the previous studies. 24, 31 Blood was modeled as two-phase Newtonian fluid (viscosity of 0.0035 kg/m·s and density of 1,060 kg/m 3 ), with platelets assumed as neutrally buoyant solid 3 µm diameter spheres. Sliding and stationary meshes were employed. 24 operating conditions of 9,000 rpm impeller speed were applied in both VADs, generating 4 and 5 l/min cardiac outputs (Cos) in HA5 and HMII, respectively-serving as the parameters for the mass flow rate inlet boundary condition (BC), with 0 pa initially applied as the pressure outlet BC. 24 Approximately 32,000 platelets were seeded and released upstream of the inflow cannulae. The amount of platelets was determined to represent a typical physiologic platelet count. 24, 31 optimized time steps of 70 and 18.5 µs were determined for HA5 and HMII, respectively, 24, 25 resulting in the corresponding degrees of the rotating impeller position per time step of 3.78° and 1° for HA5 and HMII, respectively. 24, 25 Outflow graft cannulation Human adult aorta geometry obtained from previous studies was employed (protocol approved by the Stony Brook university Institutional review Board)
. 32 An open source software, ITK-SNAp, 33 and ANSYS Gambit (ANSYS Fluent Inc., lebanon, NH) were employed for reconstructing the CT images of aorta, and a geometry representing the outflow graft was connected to the ascending aorta with end-to-side anastomotic angles of 90° and 60°. The associated volumetric meshes were generated, and an optimized mesh density of approximately 5.5M elements was determined (Figure 3, insets) .
The CFD solver, ANSYS Fluent, was used for conducting the laminar transient simulations. The modeling blood property was described in the previous section. The inlet BC of the outflow Modified from MicroMed MicroMed Cardiovascular Inc. 38 and John et al. 39 graft employed the outflow velocity profile from the previous HA5 study-9,500 rpm and 4 l/min of impeller speed and Co, respectively. 25 A complex time-dependent swirling flow, adapted from the literature, was introduced as the inlet velocity BC at the aortic root to represent the last phase of the left ventricle contraction. literature values were used to define flow rate at the brachiocephalic, left common carotid, left subclavian arteries, and descending aorta. 34, 35 Approximately 26,000 platelets, which represented a typical physiologic platelet count, 24, 31 were seeded and released upstream of the outflow cannulae. An optimized time step of 50 ms was determined, and approximately 90% of the platelets had a residence time of 1,250 ms.
Stress accumulation and probability density function The shear loading histories of the platelet trajectories, stress accumulation (SA), were computed by incorporating the cumulative linear product of the instantaneous shear stress and exposure time of each platelet trajectories, as described in detail previously. 24, 25, 28 As long-term use of cfVAD becoming more common, its possible effect on thrombogenic potential (Tp) is worth consideration. According to the desired flow rates of 4 and 5 l/ min for HA5 and HMII, respectively, platelets travel through the corresponding cfVADs 8,064 and 10,080 times throughout their average lifespan of 7 days in an adult device recipient's 5 l circulatory system. Such clinical scenarios were modeled by employing an in-house code, in which platelets were randomly reassigned to different trajectories in each successive passages to account for the fact that platelets do not necessarily flow through identical trajectories during successive passages. Accordingly, the accumulated SA values of each platelet were computed by a summation of the repeated passage SAs.
To quantitatively analyze and compare the SA values from the large number of platelet trajectories between each simulation, the probability density function (pDF) was employed to statistically represent the distribution of the SA of all trajectories in each simulation, representing the device "thrombogenic footprint". 24, 25, 28 
Results
Inflow Cannulation
The main modes of the 115° HA5 elbow angle inflow cannula pDF located at the similar SA range despite the circumferential orientation differences with the highest probability found in the 60° orientation, followed by the 30° and the 0°; on the other hand, 0° had the highest probability between the SA range of 10-30 dyne·s/cm 2 . Additionally, the shortest tail region pDF (SA > 50 dyne·s/cm 2 ) was found with the 0° circumferential orientation out of the three orientations ( Figure 4A ). Similar pDF main mode distributions and tail lengths were found in the 140° elbow angle inflow cannula pDF-the 60° main mode had slightly wider distribution toward the lower SA and the 30° main mode was slightly skewed to the right ( Figure 4A) . The HA5 repeated passage pDFs revealed that for the 115° elbow angle, the 0° circumferential orientation had the highest Tp followed in descending order by the 30° and the 60°; for the 140° elbow angle, the highest Tp was generated by the 30° circumferential orientation, followed in descending order by the 0° then the 60° (Figure 4B) . The statistics, for example, mean SA value and the percentage of platelet population which were exposed to the higher SA range (i.e., above 50 dyne·s/cm 2 ) of both single and repeated passage studies, are presented in Table 1 .
The HMII pDFs indicated that the left-shifted of the 0° main mode toward the lower SA range as compared with the other orientations; shorter tail was found at the 0° orientation tail region pDF (Figure 5A, inset) . The HMII repeated passage results revealed that the 0° circumferential orientation generated the highest Tp followed in descending order by the 30° then 60° (Figure 5B) . The statistics of both single and repeated passage HMII results are presented in Table 1 .
Outflow Cannulation
The pDF results of the 60° and 90° end-to-side anastomotic angles revealed that bimodal and unimodal distributions were observed in the 60° and 90° pDFs, respectively. The tail regions pDFs revealed that the longer tail of the 60° pDF; on the other hand, a secondary mode was observed in the 90° pDF (Figure 6A, inset) . The repeated passage results revealed two very distinct normally distributed pDFs for the two anastomotic angles (Figure 6B) . The statistics for both single and repeated passage results of the anastomotic angle studies are presented in Table 2 .
Discussion
The pharmacologic management of device-associated antithrombotic therapies remains challenging. While prior work demonstrated the efficacy of VAD design optimization methodology for reducing the overall thrombogenicity of the device itself, [24] [25] [26] [27] surgical implantation and patient anatomic variability have led to the consideration of analysis of other "VAD system" components as contributors to the overall MCS thrombogenicity. To account for these system effects, the current study modeled and quantified for the first time the thrombogenic footprint of each implantation configuration for a range of inflow and outflow geometric Figure 4 . Probability density function results of the HA5 VAD assembled to the inflow cannulae with 115° and 140° elbow angles, combined with three circumferential orientations of 0° (blue), 30° (green), and 60° (red). A: Single passage: with the 115° inflow cannula, the 60° main mode has the highest probability, and the 0° main mode has the highest probability within the SA range of 10-30 dyne·s/cm 2 (inset: zoom in of the highest SA range at the PDF tail). With the 140° inflow cannula, the 60° main mode has slightly wider distribution toward the lower SA range. B: Repeated passage PDFs: inflow cannula combined with 60° circumferential orientation generated the lowest TP independent of its elbow angle. The highest TP was found with the 0° and 30° circumferential orientations combined with the 115° and 140° elbow angle cannulae, respectively. HA5, HeartAssist 5; SA, stress accumulation; TP, thrombogenic potential; VAD, ventricular assist device; PDF, probability density function.
factors. our results clearly demonstrated that the variation of these parameters impacts the Tp of the implanted device, with each having a significant potential impact on overall MCS thrombogenicity, while indicating which implantation configurations or design factors exterior to the device itself are desirable as to achieve optimal performance of the implanted device.
The single and repeated passage models employed in the present studies provided the detail device thrombogenic footprint of the platelets flowing through the device and the long-term system Tp for an average life span of platelets. 36 Such approaches facilitated simulating a closer-to-reality physiologic scenario. Because of the randomization of the trajectories during each successive passage and the resulting cumulative effect of these repeated passages, the repeated passage pDFs are characterized by closer to a normal statistical distribution and more distinct differences than those of the single passage pDFs.
The HA5 results indicated the 140° inflow cannula, which is designed for the smaller adults or pediatric patients, is a favorable configuration for the patients whose anatomical geometries are suitable, as lower Tp was generated. Beside the options of the inflow cannula elbow angle, the HA5 inflow cannula is optimally attached to the pump with 60° circumferential orientation because of the lowest Tp this configuration generated. on the other hand, the HMII results suggested that the HMII inflow cannula is best connected to the pump with 0° circumferential orientation because of the significantly lower Tp this orientation generated. These results indicated that the optimal configuration of how the pump should be configured with respect to the inflow cannula is device dependent, despite the fact that similar design concepts may be shared.
The outflow graft anastomosis result indicated that the risk of postimplant thromboembolic complications may be reduced by connecting the outflow graft to the ascending aorta with a 60° anastomotic angle. Such result coincides with the previous studies which showed that different anastomotic angles significantly affect the aortic flow pattern. 37 In addition, the current study considered not only the outflow graft anastomotic angle but also the aortic root swirling flow induced by the last phase of ventricular contraction, thus providing a more physiologically realistic result of modeling the postimplant system thrombogenicity. As mentioned earlier, no specific instructions presently exist for surgeons with regard to detailed orientation and angulation guidelines for device and cannula implantation to optimize VAD performance and reduce thrombogenic risk. The present studies suggested that to optimize both the acute surgical and long-term medical outcome of VAD therapy, proper implantation configuration is needed to reduce the risk of postimplant thromboembolic complications.
The present studies bear certain limitations. The pump inflow conditions are affected by the ventricular contraction clinically which generates dynamic intraventricular pressure. In the current study, constant flow rates were employed to model the scenario that the device recipient is close to end-stage congestive heart failure, in which the aortic valve opening is marginal. The accuracy of transient simulations is affected by several factors, including the mesh size, platelet particle densities, time step sizes, and the simulation duration. The mesh size, particle densities, and time step sizes were carefully determined according to the mesh independence studies, the physiologic platelet count, and the corresponding impeller speeds, respectively. If a full cardiac cycle waveform had been employed, the length of the simulations would be extended to a degree that the simulations may become computationally prohibitive. Given the large size of our computational meshes needed for these FSI simulations, the aortic wall was modeled as rigid, simplifying the compliance of the aortic wall that enables the vessel to radially distend and recoil through the cardiac cycle. Despite the non-Newtonian property of human blood, the current study used Newtonian fluid to reduce the simulation complexity as the present two-phase simulations are already computationally demanding; besides, the efficacy of such approach in high shear environment was successfully demonstrated in the previous studies. 24, 25, 29, 31 lastly, platelets are continuously exposed to dynamic shear stresses while flowing in the circulation; however, the present studies calculated the stress exposure accumulated only while flowing through the implanted devices throughout the lifespan of platelets. While these values may underestimate the overall activity level of the platelets, it is clear that the platelets passages through the device are the dominant factor affecting the overall systemic thrombogenicity.
Conclusion
Ventricular assist device thrombosis persists despite pump design optimization and antithrombotic therapy. Herein, we demonstrated that VADs must be considered as part of a system of mechanical circulatory support-with inflow and outflow cannula geometries and orientation as system elements. Various geometric features related to either device design or the surgical implantation configuration, for example, the inflow cannula angle, inflow cannula orientation, and outflow cannula anastomotic angle, are additional variables that must be added to flow simulations to evaluate overall device and system postimplantation performance. Besides, significant differences in the Tp may result if the system configuration is far from optimal, which may offset any thrombogenicity reduction achieved by device optimization per se. Insights gained from this study may have direct clinical applicability to alter and optimize surgical implantation techniques, thereby enhancing the safety and efficacy of the implanted VAD. 
